Across the nation, biotech companies are faced with many challenges, most significantly the continuing arduous economic climate and increasing difficulty accessing capital. While companies in New Jersey are not immune to these factors, the state's companies, supporting organizations, and government entities are finding some success in addressing these issues by developing creative strategies to support continued innovation and growth in what Ernst & Young has termed the "new normal" in its 2010 analysis of the industry.
Collaboration and partnerships within the biotech community and between biotech companies and pharmaceutical companies are, and will continue to be, a critical component of the evolving biotech landscape. But what is becoming increasingly clear is that state, regional and national lines are no longer relevant.
To read the full, original article click on this link: Commentary: Capitalizing on Opportunities: New Jersey’s biotech sector takes international focus.
Author: DEBBIE HART
